MEDI6570

BIOLOGICAL2 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

AtherosclerosisCardiovascular DiseaseCoronary Heart Disease (CHD)

Phase 1

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

CompletedNCT03654313

MedImmune LLCAtherosclerosis, Cardiovascular Disease

Start: 2018-09-28End: 2020-07-21Updated: 2020-08-24

Phase 2

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

CompletedNCT04610892

AstraZenecaCoronary Heart Disease (CHD)

Start: 2020-11-04End: 2023-11-08Updated: 2025-02-21

Related Papers

Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results

Journal of the American Heart Association2023-01-2318 citations

Abstract 11971: Identification of Response Biomarkers and Signaling Pathways Associated With the LOX-1 Blockade by MEDI6570 in Type 2 Diabetes

Circulation2022-11-082 citations